BioSpace News Archive

Glooko, Inc. today announced the appointment of Enrique Conterno to its Board of Directors.

Revolo Biotherapeutics today announced topline data from its allergen challenge mapping study evaluating the immunologic mechanisms, safety, and tolerability of the Company’s immune-resetting drug, ‘1104, in atopic adults with moderate to severe allergy.

Rhythm Pharmaceuticals, Inc. today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 7, 2023 to report its third quarter 2023 financial results and provide a corporate update.

Fate Therapeutics, Inc. today announced that the Company will host a conference call and live audio webcast on Wednesday, November 8, 2023 at 5:00 PM ET to report its third quarter 2023.

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company) today announced that interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treatment of cystic fibrosis lung disease will be presented at the 2023 North American Cystic Fibrosis Conference (NACFC) and that it will host a live webcast to discuss the data in detail and provide a program update on Wednesday, November 1, 2023 at 4:30 p.m. ET.

Immutep Limited, is pleased to announce that it has received a A$1,134,882 cash rebate from the Australian Federal Government’s R&D tax incentive program.

Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced preclinical data supporting the safety and tolerability of the RaniPill® drug delivery platform following 60-day repeat administration.

Femasys Inc. today announced that it will highlight its product candidate in late stage clinical development, FemBloc ® , as well as showcase three of its marketed products advancing women’s health FemVue®, FemCath® and FemCerv®, at the annual meeting of the American Association of Gynecologic Laparoscopic Surgeons (AAGL) being held in Nashville, Tennessee from November 5-8, 2023.

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Flashpoint Therapeutics announced today a $10M seed financing round led by Beta Lab.